StreetInsider.com News Articles

Liquidia Technologies (LQDA) PT Raised to $65 at H.C. Wainwright

Thu, 15 Oct 2026 07:11:39 -0400

(Updated - October 15, 2026 7:11 AM EDT)

H.C. Wainwright analyst Andrew S. Fein raised the price target on Liquidia Technologies (NASDAQ: LQDA) to $65.00 (from $58.00) while maintaining a Buy rating.

The analyst commented: "Liquidia announced a global settlement with United Therapeutics (UTHR; Fein; Buy) resolving all six pending lawsuits. We view it as positive: it removes the litigation overhang and lets Liquidia focus on PAH and its pipeline. Our key takeaways: (1) PAH is secured. Liquidia conceded an indication our model had already written off in exchange for eliminating injunction risk in its core franchise, a trade we would have

Liquidia Technologies (LQDA) PT Raised to $65 at H.C. Wainwright

Thu, 15 Oct 2026 07:11:39 -0400

(Updated - October 15, 2026 7:11 AM EDT)

H.C. Wainwright analyst Andrew S. Fein raised the price target on Liquidia Technologies (NASDAQ: LQDA) to $65.00 (from $58.00) while maintaining a Buy rating.

Liquidia Technologies (LQDA) PT Lowered to $58 at Needham

Wed, 14 Oct 2026 07:41:09 -0400

(Updated - October 14, 2026 7:41 AM EDT)

Needham analyst Serge Belanger lowered the price target on Liquidia Technologies (NASDAQ: LQDA) to $58.00 (from $72.00) while maintaining a Buy rating.

The analyst commented: "LQDA and United Therapeutics (UTHR; N/R) entered into a settlement that resolves ongoing litigation btw the co's and keeps Yutrepia on the market with a PAH label without interruption. LQDA agreed to not appeal the recent 9/30/26 court ruling, and will pay UTHR $380.7MM in multiple installments in 2026/2027.

LQDA reported prelim 3Q26 Yutrepia sales of $222.7MM (vs. Street's $201.5MM), and a cash balance of ~$396MM as of 9/30/26.

The agreement

Liquidia Technologies (LQDA) PT Lowered to $58 at Needham

Wed, 14 Oct 2026 07:41:09 -0400

(Updated - October 14, 2026 7:41 AM EDT)

Needham analyst Serge Belanger lowered the price target on Liquidia Technologies (NASDAQ: LQDA) to $58.00 (from $72.00) while maintaining a Buy rating.

LQDA reported prelim 3Q26 Yutrepia sales of $222.7MM (vs. Street's $201.5MM), and a cash balance of ~$396MM as of 9/30/26.

The agreement

BTIG Upgrades Liquidia Technologies (LQDA) to Buy

Wed, 14 Oct 2026 06:07:42 -0400

BTIG analyst Julian Harrison upgraded Liquidia Technologies (NASDAQ: LQDA) from Neutral to Buy with a price target of $70.00.

The analyst comments "We are upgrading LQDA to BUY and a $70 PT (20x our 2027E FD non-GAAP EPS). Following the adverse ruling in the '327 trial two weeks ago, LQDA reached a global settlement with United Therapeutics (UTHR, Buy, $728 PT) yesterday evening that has confirmed full resolution of key ongoing legal disputes between the two companies, continuity of Yutrepia's launch in PAH, $380.7M in damages to be paid to UTHR, and discontinuation of LQDA's injected treprostinil operations. This outcome is

BTIG Upgrades Liquidia Technologies (LQDA) to Buy

Wed, 14 Oct 2026 06:07:42 -0400

BTIG analyst Julian Harrison upgraded Liquidia Technologies (NASDAQ: LQDA) from Neutral to Buy with a price target of $70.00.

BTIG Upgrades Liquidia Technologies (LQDA) to Buy

Wed, 14 Oct 2026 06:07:42 -0400

BTIG analyst Julian Harrison upgraded Liquidia Technologies (NASDAQ: LQDA) from Neutral to Buy with a price target of $70.00.

BTIG Upgrades Liquidia Technologies (LQDA) to Buy

Wed, 14 Oct 2026 06:07:42 -0400

BTIG analyst Julian Harrison upgraded Liquidia Technologies (NASDAQ: LQDA) from Neutral to Buy with a price target of $70.00.

Form 8-K Liquidia Corp For: Oct 08

Wed, 14 Oct 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20261014/27183186.html

Liquidia Technologies (LQDA) PT Raised to $33 at Wells Fargo

Wed, 14 Oct 2026 05:40:47 -0400

Wells Fargo analyst Benjamin Burnett raised the price target on Liquidia Technologies (NASDAQ: LQDA) to $33.00 (from $30.00) while maintaining a Equal Weight rating.

Liquidia Technologies (LQDA) call put ratio 1.6 calls to 1 put

Wed, 14 Oct 2026 04:32:14 -0400

Liquidia Technologies (NASDAQ: LQDA) 30-day option implied volatility is at 127; compared to its 52-week range of 74 to 183. Call put ratio 1.6 calls to 1 put into and United Therapeutics (UTHR) reached a global settlement agreement that resolves all pending litigation between the companies.

Form 4 Liquidia Corp For: Oct 09 Filed by: Schundler Russell

Tue, 13 Oct 2026 20:05:00 -0400

si-local-file:///var/storage/secattach/20261013/27182300.html

Form 4 Liquidia Corp For: Oct 09 Filed by: Saggar Rajeev

Tue, 13 Oct 2026 20:04:00 -0400

si-local-file:///var/storage/secattach/20261013/27182298.html

Form 4 Liquidia Corp For: Oct 09 Filed by: Moomaw Scott

Tue, 13 Oct 2026 20:03:00 -0400

si-local-file:///var/storage/secattach/20261013/27182297.html

Form 4 Liquidia Corp For: Oct 09 Filed by: Krepp Sarah

Tue, 13 Oct 2026 20:02:00 -0400

si-local-file:///var/storage/secattach/20261013/27182295.html

Form 4 Liquidia Corp For: Oct 09 Filed by: Kaseta Michael

Tue, 13 Oct 2026 20:01:00 -0400

si-local-file:///var/storage/secattach/20261013/27182290.html

Form 4 Liquidia Corp For: Oct 12 Filed by: Khindri Sanjeev

Tue, 13 Oct 2026 20:01:00 -0400

si-local-file:///var/storage/secattach/20261013/27182292.html

Form 4 Liquidia Corp For: Oct 09 Filed by: JEFFS ROGER

Tue, 13 Oct 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20261013/27182286.html

Form 4 Liquidia Corp For: Oct 09 Filed by: Adair Jason

Tue, 13 Oct 2026 19:59:00 -0400

si-local-file:///var/storage/secattach/20261013/27182283.html

Form 4 Liquidia Corp For: Oct 09 Filed by: Boyle Dana

Tue, 13 Oct 2026 19:59:00 -0400

si-local-file:///var/storage/secattach/20261013/27182284.html

Liquidia settles all litigation with United Therapeutics for $380.7M

Tue, 13 Oct 2026 17:51:38 -0400

Liquidia Corporation (Nasdaq: LQDA) announced a global settlement with United Therapeutics Corporation (Nasdaq: UTHR) that resolves all six pending lawsuits between the two companies, according to a press release issued Oct. 13, 2026.

Under the terms of the agreement, Liquidia will make a net payment of $175 million to United Therapeutics within 30 business days, which accounts for funds paid by United Therapeutics to Liquidia to resolve related antitrust litigation. Liquidia will then pay an additional $145.4 million in two equal installments of $72.7 million, due on or before January 31, 2027, and April 30, 2027. Separately, Liquidia will pay $60.3

Liquidia settles all litigation with United Therapeutics for $380.7M

Tue, 13 Oct 2026 17:51:38 -0400

Liquidia settles all litigation with United Therapeutics for $380.7M

Tue, 13 Oct 2026 17:51:38 -0400

Liquidia settles all litigation with United Therapeutics for $380.7M

Tue, 13 Oct 2026 17:51:38 -0400

Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH

Tue, 13 Oct 2026 17:44:00 -0400

Fully resolves all six ongoing lawsuits between the companies
Maintains uninterrupted access to YUTREPIA® for patients with pulmonary arterial hypertension (PAH)
Liquidia to pay net $380.7 million in multiple installments in 2026 and 2027, inclusive of payments to resolve antitrust litigation against United Therapeutics
Strong financial position with $222.7 million in Q3’26 YUTREPIA net product sales (preliminary, unaudited), contributing to $396.1 million in cash and cash equivalents as of September 30, 2026
Liquidia will continue to advance YUTREPIA and L606 clinical programs as previously outlined

MORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) --